Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Operating Margin (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Operating Margin data on record, last reported at 238.71% in Q4 2025.

  • For Q4 2025, Operating Margin rose 41688.0% year-over-year to 238.71%; the TTM value through Dec 2025 reached 98.22%, up 12789.0%, while the annual FY2025 figure was 98.22%, 12789.0% up from the prior year.
  • Operating Margin reached 238.71% in Q4 2025 per LCTX's latest filing, up from 102.85% in the prior quarter.
  • Across five years, Operating Margin topped out at 238.71% in Q4 2025 and bottomed at 1803.07% in Q1 2021.
  • Average Operating Margin over 5 years is 404.11%, with a median of 301.45% recorded in 2021.
  • Peak YoY movement for Operating Margin: skyrocketed 168094bps in 2022, then plummeted -36297bps in 2023.
  • A 5-year view of Operating Margin shows it stood at 301.45% in 2021, then fell by -15bps to 346.68% in 2022, then grew by 10bps to 311.1% in 2023, then skyrocketed by 43bps to 178.17% in 2024, then skyrocketed by 234bps to 238.71% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 238.71% in Q4 2025, 102.85% in Q3 2025, and 715.37% in Q2 2025.